First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer

Leyre Brizuela1,2, Isabelle Adér1,2, Catherine Mazérolles1,2,3, Magalie Bocquet1,2, Bernard Malavaud1,2,3, and Olivier Cuvillier1,2

Abstract

This is the first report of sphingosine 1-phosphate lyase (SPL) protein expression and enzymatic activity in human neoplasm. This enzyme drives irreversible degradation of sphingosine 1-phosphate (S1P), a bioactive lipid associated with resistance to therapeutics in various cancers, including prostate adenocarcinoma. In fresh human prostatectomy specimens, a remarkable decrease in SPL enzymatic activity was found in tumor samples, as compared with normal adjacent tissues. A significant relationship between loss of SPL expression and higher Gleason score was confirmed in tissue microarray (TMA) analysis. Moreover, SPL protein expression and activity were inversely correlated with those of sphingosine kinase-1 (SphK1), the enzyme producing S1P. SPL and SphK1 expressions were independently predictive of aggressive cancer on TMA, supporting the relevance of S1P in prostate cancer. In human C4-2B and PC-3 cell lines, silencing SPL enhanced survival after irradiation or chemotherapy by decreasing expression of proteins involved in sensing and repairing DNA damage or apoptosis, respectively. In contrast, enforced expression of SPL sensitized cancer cells to irradiation or docetaxel by tilting the ceramide/S1P balance toward cell death. Interestingly, the S1P degradation products failed to sensitize to chemo- and radiotherapy, supporting the crucial role of ceramide/S1P balance in cancer. Of note, the combination of SPL enforced expression with a SphK1 silencing strategy by further decreasing S1P content made prostate cancer cells even more sensitive to anticancer therapies, suggesting that a dual strategy aimed at stimulating SPL, and inhibiting SphK1 could represent a future approach to sensitize cancer cells to cancer treatments.

Mol Cancer Ther; 11(9); 1841–51. /C211 2012 AACR.

Introduction

Sphingosine 1-phosphate (S1P) has emerged as a key lipid mediator that promotes tumor cell proliferation, survival, migration, and angiogenesis (1, 2). S1P tissue level is low and kept under control through a delicate equilibrium between its synthesis and its degradation (1). It has been suggested that the balance between the levels of S1P and its metabolic precursors ceramide and sphingosine provides a rheostat mechanism that decides whether a cell dies (via ceramide or sphingosine) or proliferates and survives (via S1P; ref. 3). So far, most studies have focused on sphingosine kinase-1 (SphK1), the oncogenic enzyme converting sphingosine into the growth-promoting S1P (4). SphK1 activity is stimulated by a wide array of agonists (e.g., growth factors, hormones) to generate S1P, which then can act either extracellularly, by binding to dedicated receptors to drive paracrine or autocrine signaling cascades, or intracellularly (5). In addition, recent findings obtained on tumor tissues from patients indicate that SphK1 represents a potential prognostic marker and a viable target for therapy (6), including in prostate cancer (7). The reduction of S1P levels by SphK1 inhibition increases the efficacy of chemotherapy and radiotherapy (8, 9), whereas addition of exogenous S1P protects cancer (3) and noncancer cells (10). Surprisingly, little attention has been paid to the S1P lyase (SPL), the sole enzyme that can decrease levels of intracellular S1P by irreversible cleavage into hexadecenal and ethanolamine phosphate (11). Recent studies—mostly conducted in noncancer cells—have shown that ectopic expression of SPL results in increased sensitivity to stress, including serum starvation (12), chemotherapy (13, 14), and irradiation (15). More importantly, in vivo subcutaneous implant of SPL−/− murine embryonic fibroblasts resulted in tumor formation, suggesting a tumor suppressive capacity for SPL (16) in opposition to the oncogenic
role of SphK1 (17). Despite the fact that mRNA SPL was found downregulated in human colorectal carcinomas (14), the evidence of protein expression and enzymatic activity changes in human cancer tissues that would implicate SPL is lacking.

In this study, we aimed to analyze the expression and enzymatic activity of SPL in tissue microarrays (TMA) and fresh human prostate cancer specimens. We report for the first time that both SPL expression and activity are downregulated in cancerous tissues, and establish a significant relationship between loss of SPL expression and prostate cancer aggressiveness. In addition, we find an opposite relationship between the levels of SPL and SphK1 protein expression and enzymatic activity. Poorly differentiated cancers exhibited low SPL and high SphK1 expression, pointing out the potential influence of S1P in prostate carcinogenesis. On the basis of this original clinical information, the potential role of SPL in regulating sensitivity/resistance to various anticancer therapies (radiotherapy, chemotherapy) was investigated in canonical human PC-3 and C4-2B prostate cancer cell lines. We suggest that a dual strategy aimed at stimulating SPL, and inhibiting SphK1 could represent a future approach to sensitize cancer cells to cancer treatments.

Materials and Methods

Chemicals and reagents

Culture medium, serum, and antibiotics were from Invitrogen. [γ-32P]ATP, serine L-[^3H (G)], D-erythro-[3-3H] sphingosine, and [methyl-3H] thymidine were from Perkin-Elmer. Silica gel 60 TLC plates were from VWR. Sphingosine was from Biomol. MTT, umbelliferone were from Sigma. Brain cereamide extract and D-erythro-S1P were from Avanti Polar Lipids.

Cell models

PC-3 and C4-2B cell lines were from DSMZ and Viromed, respectively. C4-2B is a castration-resistant prostate cancer cell line isolated from the bone metastasis of a mouse xenograft inoculated with C4-2 cells, a subline of LNCaP cells. Cells were cultured in RPMI-1640 containing 10% FBS at 37°C in 5% CO2 humidified incubators. GFP/Confocal microscopy, growth curve analysis, and PC-3/SPL2, respectively. Cell lines were routinely verified by the following tests: morphology check by an enhanced chemiluminescence detection system (Pierce) using anti-rabbit or anti-mouse horseradish peroxidase (HRP)–conjugated IgG (Bio-Rad). Equal loading of protein was confirmed by probing the blots with the mouse anti-tubulin (clone DM1A; Santa Cruz) antibody. Densitometry quantitation was determined using ImageJ software (NIH).

Western blot analysis and antibodies

Mouse anti-SPL (Sigma), mouse anti-γH2AX (clone JBW301; Millipore), rabbit anti-caspase-3 (clone 8G10; Cell Signalling), rabbit anti-PARP (Cell Signalling), mouse anti-GFP (clone 1GF-2A3; Euromedex) were used as primary antibodies. Proteins were visualized by an enhanced chemiluminescence detection system (Pierce) using anti-rabbit or anti-mouse horseradish peroxidase (HRP)–conjugated IgG (Bio-Rad). Equal loading of protein was confirmed by probing the blots with the mouse anti-tubulin (clone DM1A; Santa Cruz) antibody. Densitometry quantitation was determined using ImageJ software (NIH).

X-ray irradiation

Irradiation was carried out in a Faxitron Rx-650 irradiator (Faxitron X-ray Corporation) at a dose rate of 0.48 Gy/min.

SPL activity

SPL activity determination was conducted as described (23), with little modifications. The assay was carried out in 96-well plates. The incubation mixture consisted of 65 μL of cell lysate or prostate tissue sample (8–10 mg protein/mL), 15 μL of coumarinic sphinganine 1-phosphate analog substrate solution (200 μmol/L final concentration), 25 mmol/L Na3VO4 (5 μL, 0.5 mol/L), 25 mmol/L NaF (5 μL, 0.5 mol/L), and 0.25 mmol/L pyridoxal phosphate (5 μL, 5 mmol/L), 0.5 mmol/L EDTA (5 μL, 10 mmol/L), 2 mmol/L DTT (2 μL, 0.1 mol/L). The cells lysates were harvested by trypsinization, washed with PBS 1X, and resuspended in 0.5 mol/L potassium phosphate buffer pH 7.4 (8–10 mg protein/mL). The prostate tissue samples were disrupted directly in the potassium phosphate buffer with the help of an Ultraturrax homogenizer.

Radiation survival determination

Survival after irradiation was defined as the ability of the cells to maintain their clonogenic capacity and to form colonies. Cells were plated from exponentially growing cell culture at 1,000 to 1,500 cells per well in 6 well-plates 18 hours before irradiation. Single doses ranging from 2 to 6 Gy were delivered. Colonies were fixed and stained with crystal violet (2 mg/mL in 150 mmol/L NaCl) for 20 minutes. Survival clones were counted 6 days after irradiation (20).

RNA interference experiments

For the siRNA experiments, 21 nucleotide complementary RNAs with symmetrical 2 nucleotide 3' overhangs were obtained from Sigma to the following regions of human SPL: bases 409–429 (SPL1a), bases 656–676 (SPL1b), or bases 1653–1673 (SPL1c). Human SphK1–specific siRNA has been previously reported (21, 22), and aleatory sequence scrambled siRNA was from Eurogentec. Transfections were carried out using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions.

Cell viability and proliferation assays

Cell viability was determined by MTT bromide assay (18). The [1^H]thymidine cell proliferation assay was carried out as previously reported (19).
(T25 basic). The cell or tissue suspension was frozen by immersing the tube in liquid nitrogen and then it was thawed at 25°C (water bath). After gentle mixing, the freeze-thaw cycle was repeated 5 times. For the substrate solution, 5 μL of a 4 mmol/L stock solution in 0.005 N HCl in MeOH were taken, the solvent was removed under nitrogen, and the substrate was resuspended with 20 μL of PBS 1X and sonicated for 1 minute. The plate containing the final reaction mixture was incubated at 37°C for 18 hours in the dark, and after this time, the reaction was stopped with MeOH (50 μL/well) and 100 mmol/L glycine/NaOH buffer (100 μL/well). After one hour in the dark, the fluorescence intensity was measured at 355/460 nm. Upon cleavage of the coumarinic sphinganine 1-phosphate analog substrate by SPL, an aldehyde is produced, which then undergoes subsequent β-elimination to release the fluorescent product umbelliferone and acrolein. A calibration curve was made with umbelliferone in the 0.01 to 100 μmol/L concentration range prepared in the same solution.

**SphK1 and serine palmitoyltransferase activities**

The determination of SphK1 and serine palmitoyltransferase (SPT) activities were conducted as previously reported (24, 25).

**Mass measurement of ceramide, sphingosine, and S1P**

The protocols for measurement of ceramide, sphingosine, and S1P have been described in detail previously (9, 26).

**Tissue procurement**

SPL pattern of expression in prostate tissue was studied in specimens obtained from our institution tissue biorepository after Institutional Review Board approval and informed consent. They consisted of 13 consecutive patients undergoing laparoscopic radical prostatectomies conducted for clinical T1c–T2c, with at least 2 positive biopsies from January to March 2011.

**Immunohistochemistry**

TMA sections representative of prostate cancer (n = 88 in duplicates) were used to report SphK1 and SPL expression in relation to cancer differentiation. All sections were deparaffinized, hydrated, boiled with 10 mmol/L of citrate buffer (pH 6) for 30 minutes, treated with 0.3% H2O2 for 5 minutes, precubated in blocking solution (1% bovine serum albumin in PBS) for 10 minutes at room temperature and incubated with the primary antibody [anti-SphK1; ref. 27] diluted 1:100 or anti-SPL (Sigma) diluted 1:100 for 4 hours at 4°C. The sections were then washed with PBS and processed with the 2-step EnVision+ HRP DAKO system (Dako). Tumor Gleason sum was recorded for each individual microarray, and as proposed by Rubin to report immunohistochemical results in prostate cancer (28), the expression was scored as negative (1), faint/equivocal (2), moderate (3), or strong (4). The pattern of SPL expression was recorded as diffuse cytoplasmic, luminal, or both.

**Statistical analysis**

The statistical significance of differences between the means was evaluated using the unpaired Student t or the one-way ANOVA tests. All statistical tests were 2-sided, and the level of significance was set at P < 0.05. Calculations were done using Instat 3 (GraphPad Software). For immunohistochemistry studies, the relationship between Gleason Sum (GS ≤ 3 + 4 vs. GS ≥ 4 + 3) and SPL and SphK1 expression (negative and faint/equivocal vs. moderate or strong) was analyzed by Pearson test. Statistical significance was set at a P value less than 0.05, all reported values are 2-sided. To investigate whether SPL and SphK1 patterns of expression were independently predictive of Gleason score, we then conducted a logistic regression analysis with immunohistochemistry variables as dependent variables and Gleason score as independent variable.

**Results**

**SPL expression and enzymatic activity are downregulated in cancer versus noncancer tissue in patients and associated with tumor grade**

SPL expression was restricted to the epithelial layer, with no staining evidenced in the stromal compartment of the gland (Fig. 1A). Diffuse and intense cytoplasmic expression of SPL (Fig. 1A), reinforced at the luminal aspect of the gland, was observed in noncancer glands (strong expression, expression score 4, *). Expression in cancer was strikingly different and related to grade. Whereas well-differentiated cancers (Gleason score ≤3 + 4, Fig. 1B) showed conserved pattern of expression (moderate expression, expression score 3, *), poorly differentiated cancer (Gleason score ≥4 + 3) were characterized by equivocal (Fig. 1C, expression score 2) or abrogated cytoplasmic expression (Fig. 1D, expression score 1). The pattern of expression of SphK1 has been previously reported from the same TMA (7). Semiquantitative analysis (Table 1) evaluated the relationship between Gleason score and SPL and SphK1 expressions. Conserved patterns of SPL expression were associated with lower Gleason scores as compared with negative or equivocal SPL expression (P = 0.00003). On the other hand, strong SphK1 expression correlated with higher Gleason scores (P = 0.019) than negative or equivocal SphK1 staining. The independent value of SPL and SphK1 expression was then sought by logistic regression analysis on a subset of 139 spots, in which SPL and SphK1 expressions were both available. SPL loss (P = 0.002) and SphK1 upregulation (P < 0.01) were shown to be independently predictive of aggressive cancer. As shown in Fig. 2B, low SPL with high SphK1 expression was associated with high Gleason score (85% of the TMA spots were poorly differentiated cancers and 15% well-differentiated cancers), whereas low Gleason score cancers exhibited the opposite pattern. To further look for a relationship between SPL and SphK1 expressions, we quantified SPL and SphK1...
enzymatic activities in fresh prostatic tissues obtained from 13 consecutive patients undergoing radical prostatectomy. SPL activity was markedly diminished in tumor samples (Fig. 2B) accounting for a statistically significant ($P = 0.0004$) 30% decrease in cancer tissue, as compared with the individual noncancer counterpart. Using the same extracts, SphK1 enzymatic activity was found 2-fold upregulated in cancer (Fig. 2C), in line with our previously published data (7). Of note, concordant results were found from protein expression (Fig. 2A) and enzymatic activity experiments (Fig. 2B and C), in human prostate cancer tissues. Collectively, these results established that the S1P producing SphK1 enzyme is overexpressed in cancer, whereas the S1P degrading SPL enzyme is underexpressed, highlighting the importance of S1P in prostate cancer.

**Modulating SPL activity impacts S1P metabolism**

First, downregulation of SPL was conducted by siRNA strategy with 3 different siRNAs tested and validated by assessing protein expression and enzymatic activity. The siSPL1b induced a 50% decrease in SPL expression

<table>
<thead>
<tr>
<th>Table 1. Semiquantitative analysis of the relationship between SPL or SphK1 expression and Gleason score in prostate cancer TMA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SPL expression</strong></td>
</tr>
<tr>
<td>Negative or faint/equivocal</td>
</tr>
<tr>
<td>Moderate or strong</td>
</tr>
<tr>
<td>$n = 47$</td>
</tr>
<tr>
<td><strong>SphK1 expression</strong></td>
</tr>
<tr>
<td>Negative or faint/equivocal</td>
</tr>
<tr>
<td>Moderate or strong</td>
</tr>
<tr>
<td>$n = 41$</td>
</tr>
</tbody>
</table>
FIG. 3A) and enzymatic activity (Fig. 3B) in both PC-3 and C4-2B cell lines. The combination of the 3 sequences (SPL1a+SPL1b, SPL1a+SPL1c, SPL1b+SPL1c, and SPL1a+SPL1b+SPL1c) did not improve the efficacy of the transfection (data not shown). The silencing of SPL activity was accompanied by a significant rise in intracellular S1P content (Fig. 3C).

Second, stable overexpression of SPL was carried out in PC-3 cells. As shown in Fig. 4A, transfection efficiency was verified in 2 different clones (PC-3/SPL1 and PC-3/SPL2). As anticipated, SPL enzymatic activity was clearly enhanced (Fig. 4B) and S1P content significantly reduced, yet not to the same extent (Fig. 4B). The content in proapoptotic ceramide was significantly augmented (Fig. 4B), possibly as a consequence of the stimulation of SPT (Fig. 4B), a key enzyme in the de novo pathway of ceramide generation. Interestingly, the content of proapoptotic sphingosine (Fig. 4B) was reduced, whereas SphK1 activity was increased in PC-3 overexpressing SPL (Fig. 4B). These data indicated that PC-3/SPL cells may struggle to survive to the enforced degradation of S1P and generation of ceramide by enhancing S1P production, through increased SphK1 activity as confirmed by the decrease in sphingosine, its substrate. However, this adaptive prosurvival mechanism is not sufficient enough as an important pool of S1P (about 30%, Fig. 4B) is degraded because of overexpression of SPL. Further analysis of SPL-overexpressing PC-3 cells indicated a different behavior compared with PC-3/Neo control cell line. PC-3–overexpressing SPL cell lines showed a reduced (about 30%) proliferation rate (Fig. 4C) as compared with PC-3/Neo cells, likely a consequence of a higher basal rate of apoptosis (Supplementary Fig. S1), in line with their relative changes in ceramide and S1P levels (Fig. 4B).

OPPOSITE EFFECTS OF SPL DOWNREGULATION AND OVEREXPRESSION WITH REGARD TO IRRADIATION
As compared with the scrambled RNA control counterparts, the knockdown of SPL activity by RNA interference strongly enhanced survival after irradiation in PC-3 (Fig. 5A) and C4-2B (Supplementary Fig. S2A) cells. The radioprotective effect of SPL inhibition was due to S1P, as its addition to the culture medium of PC-3 and C4-2B wild-type cells before irradiation mimicked a radiation-resistant phenotype (Fig. 5A and Supplementary Fig. S2B). In contrast, invalidation of SphK1 by siRNA (21) rendered cells more sensitive to irradiation in PC-3 (Fig. 5A) and C4-2B cells (Supplementary Fig. S2A). Although irradiation causes a variety of lesions in DNA, double-strand breaks (DSB) are principally responsible for radiation lethality. One early marker of DSB is the phosphorylation of H2AX, which is usually referred to as γ-H2AX. Two Gy of irradiation induced H2AX phosphorylation in scrambled RNAi-transfected PC-3 (Fig. 5B) and C4-2B (Supplementary Fig. S2C) cells. In SPL-silenced cells, irradiation-induced H2AX phosphorylation was significantly lower than in scramble RNATransfected cells (Fig. 5B), consistent with a higher resistance to apoptosis. Taken together, these results strongly suggest that the levels of S1P and ceramide in SPL-silenced cells are insufficient for survival and that SphK1 must be activated to compensate for the lower levels of S1P present.

Figure 2. An inverse relationship exists between SPL and SphK1 protein expression and enzymatic activity in human prostate cancer. A, semiquantitative analysis of the relationship between combined SPL and SphK1 expression and Gleason score. Staining intensity was scored as low (sum of negative and faint/equivocal) and high (sum of moderate and strong). The n value represents the number of spots for which both SphK1 and SPL expression were evaluated (total n = 139). SPL (B) and SphK1 (C) activities were quantified in 13 individual pairs of cancer and noncancerous lesions (see Material and Methods section, tissue procurement). Median SPL activities were 6.0 (95% CI, 5.2–6.2) and 4.0 (95% CI, 3.1–4.2) pmol/min/mg of protein in noncancerous and tumor samples, respectively (P < 0.0001). Median SphK1 activities were 88 (95% CI, 71–129) and 259 (95% CI, 223–289) pmol/min/mg of protein in noncancerous and tumor samples, respectively (***, P < 0.0001).
phosphorylation was decreased, suggesting less DNA damage in these cells (Fig. 5B and Supplementary Fig. S2C). Conversely, the silencing of SphK1 in PC-3 (Fig. 5B) and C4-2B (Supplementary Fig. S2C) cells caused a robust increase of γ-H2AX.

The survival capability of SPL-overexpressing cell lines after irradiation was significantly reduced as compared with PC-3/Neo control cells (Fig. 5C). PC-3/SPL1 cells showed an increased γ-H2AX expression before and after 2-Gy X-irradiation, as well as a delay in the recovery of the basal level expression (Fig. 5D). These results were confirmed by immunofluorescence staining and fluorescence-activated cell sorting (data not shown), and similar results were obtained with the PC-3/SPL2 cell line (data not shown). Importantly, the combination of SPL enforced expression with a siRNA strategy against SphK1 by further lowering S1P content (data not shown) rendered PC-3 cells even more sensitive to irradiation (Fig. 5C).

Chemotherapy-induced cell death is inhibited by SPL knockdown and potentiated by SPL overexpression

Docetaxel is the current standard of care for the treatment of metastatic prostate cancer. As compared with the siScramble-pretreated PC-3 or C4-2B cells, the silencing of SPL significantly inhibited the loss of cell viability.
observed after treatment with increasing doses of docetaxel (Fig. 6A). In prostate cancer cells, docetaxel-induced cell death involves the processing of caspases, particularly the executioner caspase-3, an event associated with the activation of PARP, a canonical caspase-3 substrate (29). In scrambled RNAi-transfected PC-3, a diminution of both 32 kDa unprocessed caspase-3 and 116 kDa unprocessed PARP expression during treatment with docetaxel was found (Fig. 6C). However, no activation of caspase-3 and PARP were observed in SPL-silenced cells (Fig. 6C), consistent with inhibition of caspase-3 activity and the notion that S1P inhibits activation of caspases that cleave PARP (30). In contrast, overexpression of SPL in PC-3 cells markedly diminished cell viability of cells treated with docetaxel (Fig. 6B) and amplified activation of both caspase-3 and PARP processing (Fig. 6D). In line with the data obtained with radiotherapy, the combination of SPL enforced expression with an siRNA strategy against SphK1 rendered PC-3 cells even more sensitive to irradiation (Fig. 6B).

Discussion

Because of the importance of S1P in cancer (1, 2), considerable interest has developed in understanding the function of the enzymes implicated in its metabolism. Concordant studies have shown that SphK1, responsible for S1P synthesis, is instrumental to cancer promotion, progression, and resistance to treatment in vitro and in vivo, notably in prostate cancer (9, 19, 21, 22, 31). In complement to preclinical literature, we recently reported the relationship between increased SphK1 activity and relevant clinical features in human prostate cancer resection specimens confirming a central role for the SphK1/S1P signaling in prostate cancer (7). S1P is irreversibly degraded by SPL generating 2 products, ethanolamine phosphate and a long-chain aldehyde (32).
findings showed the downregulation of SPL at the mRNA level in human colorectal carcinomas (14) and in Min mouse intestinal adenomas, suggesting that SPL loss may correlate with and/or contribute to intestinal carcinogenesis (14). In this study, we establish that both protein expression and enzymatic activity of SPL are downregulated in cancer versus noncancer tissue in prostate cancer patients and associated with tumor grade. Statistical
analyses show that loss of SPL expression is significantly associated with aggressive cancers (high Gleason score). More importantly, SPL loss of function is accompanied by a concomitant increase in SphK1 expression. Aggressive poorly differentiated cancers exhibit low SPL and high SphK1 expression, whereas well-differentiated cancers display the opposite pattern. These data are confirmed in fresh human prostatectomy specimens in which significant decrease in SPL enzymatic activity and increase in SphK1 activity are found. The opposite relationship between the levels of SPL and SphK1 protein expression and enzymatic activity, therefore, supports the importance of SPL in prostate cancer. In colon cancer, although SPL mRNA expression was found to be downregulated in 8 of 10 samples, Saba and collaborators did not find that SphK1 was differentially expressed in tumors (14). To the best of our knowledge, we report for the first time such inverse relationship between enzymes playing antagonistic effects on the level of S1P. Our data therefore warrant further clinical investigations of paired SphK1 and SPL expression in other tumor locations.

The role of SPL in regulating sensitivity/resistance to chemotherapeutics has been investigated in several systems. The sensitizing effect to diverse agents (platinum salts, doxorubicin, and etoposide) associated with SphK1 overexpression in *Disctyostelium*, HEK293, and lung cancer A549 cells has been reported previously (13, 33). In line with these studies, we found that enforced expression of SPL potentiates the response to docetaxel, the standard chemotherapeutics has been investigated in several systems. The sensitizing effect to diverse agents (platinum salts, doxorubicin, and etoposide) associated with SphK1 overexpression in *Disctyostelium*, HEK293, and lung cancer A549 cells has been reported previously (13, 33). In line with these studies, we found that enforced expression of SPL potentiates the response to docetaxel, the standard chemotherapy in prostate cancer, whereas SPL silencing prevents cell death. With regard to irradiation, we show that silencing SPL enhances survival after irradiation by decreasing expression of γ-H2AX as well as DNA-PKcs-P and ATM-P (data not shown), proteins involved in the sensing and repairing of DNA DSBs. As expected, enforced expression of SPL sensitizes cancer cells to
irradiation. Our findings are in line with earlier studies showing the radioprotective capability of SPL notably in vivo (10, 34). The prosurvival effect of SPL silencing could indeed be attributed to S1P accumulation, as this effect was mimicked by addition of exogenous S1P to prostate cancer cells. Importantly, the combination of SPL overexpression with a SphK1 silencing by further decreasing S1P content make prostate cancer cells even more sensitive to irradiation or to chemotherapy, suggesting that a dual strategy aimed at stimulating SPL and inhibiting SphK1 could represent a future approach to potentiate sensitization of cancer cells. In contrast, the silencing of SphK2 isoform activity (which is minor in the PC-3 and C4-2B prostate cancer cell models as compared with SphK1 activity) did not sensitize to docetaxel nor to radiotherapy (Supplementary Fig. S3).

The sensitization induced by SPL overexpression is likely to be attributed to its effect on the ceramide/S1P balance (increased ceramide and decreased S1P), rather than increased formation of SPL reaction products. We found that SPL overexpression is associated with increased ceramide and decreased sphingosine and S1P levels. We also report that cancer cells overexpressing SPL may struggle to survive to the SPL-mediated degradation of prosurvival S1P and generation of proapoptotic ceramide by enhancing S1P production through increased SphK1 activity that could explain the decrease in sphingosine we observed. We suggest a mechanistic linkage between SphK1 and S1P activities. If the overexpression of SPL is accompanied with increased SphK1 activity (Fig. 4), it seems that overexpression of SphK1 is also associated with higher SPL activity (data not shown). Similarly, the silencing of SphK1 induces a decrease in SPL activity, whereas the silencing of SPL triggers inhibition of SphK1 activity (data not shown). Overall, the silencing or the enforced expression of one enzyme impacts the activity of the other one, suggesting a compensatory mechanism between SphK1 and SPL exists to maintain a certain level of S1P to ensure cell survival. Contradictory results about the mechanism of ceramide production under enforced expression of SPL have been reported in the literature. Using the same HEK293 cell model, Reiss and colleagues (12) showed a de novo synthesis of ceramide, whereas Kumar and colleagues ruled out this mechanism (15). Our results suggest a de novo synthesis through SPT activation. Additional data are needed to help clarify these divergent results. With regard to the reaction products of SPL, they are unlikely to account for the sensitizing properties of SPL. Interconvertible derivatives of S1P degradation product hexadecenal, namely hexadecanol and palmitate, although inducing a limited loss of cell viability by themselves, do not sensitize to irradiation nor to chemotherapy (Supplementary Fig. S4).

Overall, our clinical observations showing that SPL is downregulated in prostate cancer, whereas SphK1 is upregulated suggests that a therapeutic approach combining the inhibition of S1P production associated with a stimulation of its degradation should have a favorable therapeutic index, notably in combination with radio- or chemotherapy.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: L. Brizuela, I. Ader, O. Cuvillier
Development of methodology: L. Brizuela, I. Ader, B. Malavaud
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L. Brizuela, I. Ader, C. Mazzerolles, M. Bocquet, B. Malavaud
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L. Brizuela, I. Ader, C. Mazzerolles, M. Bocquet, O. Cuvillier
Writing, review, and/or revision of the manuscript: L. Brizuela, C. Mazzerolles, B. Malavaud, O. Cuvillier
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L. Brizuela, C. Mazzerolles
Study supervision: L. Brizuela, C. Mazzerolles, O. Cuvillier

Acknowledgments
The authors thank Dr. Saba (Children’s Hospital Oakland Research Institute, Oakland, CA) for helpful advices and for providing GFP-tagged wild-type and mutant human SPL cDNA; Dr. Casas and Dr. Fabriás (Institut de Quimica Avancada de Catalunya, Barcelona, Spain) for providing us SPL substrate; and Ms. Maheo (CHU Rangueil, Toulouse, France) for technical expertise.

Grant Support
O. Cuvillier was supported by the Association pour la Recherche sur le Cancer (ARC), the Ligue Nationale contre le Cancer (Equipe Labellisée LIGUE 2011), the Institut National du Cancer (INCa), and the Association pour la Recherche sur les Tumeurs de Prostate (ARTP).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 7, 2012; revised June 6, 2012; accepted June 20, 2012; published OnlineFirst July 10, 2012.

References
Molecular Cancer Therapeutics

First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer

Leyre Brizuela, Isabelle Ader, Catherine Mazerolles, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at:</th>
<th>doi:10.1158/1535-7163.MCT-12-0227</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at:</td>
<td><a href="http://mct.aacrjournals.org/content/suppl/2012/07/10/1535-7163.MCT-12-0227.DC1">http://mct.aacrjournals.org/content/suppl/2012/07/10/1535-7163.MCT-12-0227.DC1</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 34 articles, 14 of which you can access for free at:</th>
<th><a href="http://mct.aacrjournals.org/content/11/9/1841.full#ref-list-1">http://mct.aacrjournals.org/content/11/9/1841.full#ref-list-1</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 3 HighWire-hosted articles. Access the articles at:</td>
<td><a href="http://mct.aacrjournals.org/content/11/9/1841.full#related-urls">http://mct.aacrjournals.org/content/11/9/1841.full#related-urls</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
<td></td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link <a href="http://mct.aacrjournals.org/content/11/9/1841">http://mct.aacrjournals.org/content/11/9/1841</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</td>
<td></td>
</tr>
</tbody>
</table>

Published OnlineFirst July 10, 2012; DOI: 10.1158/1535-7163.MCT-12-0227